Large Volume Wearable Injectors Market (4th Edition), 2018-2030

Large Volume Wearable Injectors Market (4th Edition), 2018-2030

INTRODUCTION
Chronic clinical conditions, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are considered to be among the leading causes of death and disability across the world. Recently, the Center for Managing Chronic Disease at the University of Michigan reported that over 50% of the global population is currently suffering from some form of chronic disease. The past few years have witnessed ground breaking advances in the process of drug development and introduction of several innovative pharmaceutical interventions for the treatment of a number of chronic diseases. However, majority of the available treatment options require parenteral administration, frequent dosing, involve repeated hospital visits and are associated with multiple other concerns, such as dosing and medication errors, risk of microbial contamination and needlestick injuries. These challenges represent a substantial threat to medication adherence and, thereby, are likely to significantly impact therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions to alleviate the pressing concerns associated with the administration of both conventional and novel drug / therapy molecules. Amongst modern drug delivery practices, the concept of self-injection has facilitated advanced medications to be administered beyond the clinical setting. This has also served to reduce healthcare costs, improve therapy adherence and optimize the utilization of healthcare resources per treatment.

The self-injection devices market is currently characterized by the presence of a myriad of advanced and innovative drug delivery solutions, equipped with a variety of user-friendly features. Notable examples of such products include prefilled syringes, reusable and disposable pen injectors, autoinjectors and large volume wearable injectors. Large volume wearable injectors are capable of drug delivery primarily via the subcutaneous route and have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as most biologics) in large volumes (more than 1 ml), offering numerous benefits, such as ease-of-use, reduced chances of dosing-related errors, integrated safety mechanisms, and an almost negligible risk of needlestick injuries. It is worth highlighting that such devices have captured the interest of several stakeholders in this industry to deliver various insulin and non-insulin drugs. Moreover, the field is witnessing emergence of other technological advancements, such as integrated mobile applications with smart health monitoring and other interesting features (such as provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts.

SCOPE OF THE REPORT
The “Large Volume Wearable Injectors Market (4th Edition), 2018-2030” report features an extensive study of the current market landscape and the likely future evolution of self-injection devices, over the next twelve years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting. Amongst other elements, the report includes:

A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. It features information on current development status of various products (under development and commercialized), type of device (patch pump / injector and infusion pump / injector), type of dose administered (continuous and bolus), route of administration (subcutaneous and others), usability (disposable and reusable), mechanism of action (driving force), mode of injection (needle, needle / cannula and needle / catheter), maximum volume of the device and availability of connected mobile application.

A comprehensive product competitiveness analysis of all large volume wearable injectors that we came across, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.

Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.

An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on patent type, patent offices, CPC classification, emerging areas (in terms of number of patents filed / granted) and leading industry players (in terms of size of intellectual property portfolio).
A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform from 2013 to 2018 (till September).

A comprehensive clinical trial analysis of completed, ongoing and planned studies of various large volume wearable injector products. For the purpose of this analysis, we considered the clinical studies that started in 2010, and analyzed them on the basis of various parameters, such as trial start year, current trail status, current trial phase, study design, targeted therapeutic area, study focus and clinical outcomes.

A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. It includes short descriptions of the manufacturing services provided by contract service providers in the making of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.

A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, based on an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the therapeutic area, geographical distribution of the market (North America / Europe / Asia Pacific / RoW), type of device (patch pump / injector and infusion pump / injector) and usability (reusable / disposable). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (alphabetical order of companies):
Menachem Zucker (VP and Chief Scientist, Elcam Medical)
Michael Hooven (CEO, Enable Injections)
Mark Banister (CEO, Medipacs)
Pieter Muntendam (President and CEO, scPharmaceuticals)
Mindy Katz (Director of Product, Sorrel Medical)
Jesper Roested (CEO, Subcuject)
Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)
Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Over 50 large volume wearable injectors are either commercialized and / or are under development for delivery of a variety of drugs. Devices designed for administration of non-insulin drugs have a high storage capacity and are being developed for delivery of high viscosity formulations. In fact, around 17% of such devices have the capability to hold 10-15ml of drug while 23% of the devices have a maximum storage capacity of more than 15 ml. Such devices are designed either for bolus dosing (40%), or continuous dosing (40%); there are certain products that have been designed to administer both continuous and bolus doses of drugs (20%).

2. More than 10 drug device combinations are currently developed / being evaluated for delivery of non-insulin drugs; of these, two drug device combinations are already approved by the USFDA; these are Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Pushtronex™ System (Amgen / West Pharmaceuticals). In addition, there are several other drug-device combinations that are being evaluated in clinical studies; examples include (in alphabetical order, no selection criteria) ND0701 (Neuroderm), scWear Infusor (SteadyMed Therapeutics) and Herceptin SC® Injector (Roche).

3. Specifically for insulin delivery, close to 30 devices are being developed / approved. Of these, over 60% of the devices are already marketed. Examples include (in alphabetical order, no selection criteria) ACCU-CHEK® Combo System (Roche), MiniMed™ 630G Insulin Pump System (Medtronic), PAQ®, 3-Day Basal and Bolus Delivery (CeQur)and t:slim X2™ Insulin Pump (Tandem Diabetes Care). It is worth noting that specifically for the delivery of insulin, the market for large volume wearable injectors is anticipated to reach over USD 1.5 billion by 2030, representing a CAGR of close to 5%.

4. The innovation in the field is primarily being driven by start-ups / small companies. Of all the companies developing large volume wearable injectors for non-insulin drugs, 50% are based in North America, primarily in the US. Examples of firms based in this region include (in alphabetical order, no selection criteria) Enable Injections, Medipacs, SteadyMed Therapeutics, scPharmaceuticals and West Pharmaceutical Services. Examples of start-ups based in different geographical regions that have undertaken initiatives in this domain include (in alphabetical order, no selection criteria) Debiotech, Subcuject, ViCentra, Weibel CDS and Eoflow. In addition, a number of established companies are also making substantial contributions in this field; prominent players include (in alphabetical order, no selection criteria) 3M, Becton Dickinson, Insulet, West Pharmaceutical Services and Ypsomed.

5. The development process of high-volume drug injector devices is complex due to the involvement of multiple components, which include both electrical and mechanical modules. Therefore, several device developers have opted to recruit the services of CMOs for manufacturing their proprietary drug delivery devices. Examples of companies that claim to provide manufacturing services to large volume drug delivery device developers include (in alphabetical order, no selection criteria) Baril Corporation, Daikyo Seiko, Flex International, Haselmeier, Phillips-Medisize, Vetter Pharma and Zollner.

6. Close to 2,000 patents pertaining to the abovementioned devices have been filed till 2018. An analysis of these patents revealed that automated self-injection devices, with advanced features, are gradually gaining traction amongst patients with chronic disorders. Some of the advanced features integrated with the delivery devices include automatic reconstitution / priming mechanisms, provisions for audio and visual indications, error alerts and remote monitoring capability through connected devices. Examples of large volume wearable injectors that have been designed to be connected to smart devices include (in alphabetical order, no selection criteria) BD Libertas™ Wearable Injector (Becton Dickinson), Omnipod (Insulet), SmartDose® Generation I (West Pharmaceutical Services) and Subcuject Wearable Bolus Injection (Subcuject).

7. An analysis of clinical studies that are being / have been conducted to evaluate the combinations of drugs and large volume wearable injectors reveal that close to 50% trials assessed the potential of using large volume wearable injectors for delivery of drugs intended for the treatment of neurological disorders. This is followed by the trials conducted to evaluate the effect of large volume wearable injectors in patients suffering from cardiovascular disorders (23%) and cancer (13%).

8. Out of various marketed / under development drug molecules, close to 80 drugs demonstrated a relatively higher potential to be delivered via large volume wearable injectors and are most likely to be evaluated in different drug-device combinations in the near future. Of these, 90% are biologics and 10% are small molecules. These drugs (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems.

9. The market for large volume wearable devices for delivery of non-insulin drugs is expected to grow at an annualized rate of close to 40% between 2018 and 2030. It is worth noting that disposable injectors are anticipated to capture over 50% of the market share due to the safety concerns reported by the use of reusable injectors. Further, over 60% share of revenues is anticipated to be distributed between North America and Europe. However, we believe that certain counties in Asia Pacific are likely to grow at a faster rate as compared to other regions over the coming decade; this can be attributed to the increasing incidence of chronic disorders in these regions and a relatively less stringent regulatory environment. Specifically, neurological and oncological disorders are anticipated to capture a significantly higher market share in the future.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the large volume wearable injectors market in the short-mid term and long term.

Chapter 3 provides a general introduction to large volume wearable injectors, highlighting the growing demand for medical devices that enable self-administration. The chapter lays emphasis on the need for such devices, in terms of the rising incidence and prevalence of chronic diseases. Subsequently, it provides an overview of the different types of self-injection devices available in the market, listing their various advantages. It also features a brief discussion on the concerns related to the use of such devices.

Chapter 4 presents separate lists, highlighting large volume wearable injectors capable of delivering any suitable drug and drug device combinations designed for delivery of specific drugs, respectively. In addition, the chapter includes a detailed analysis of these lists based on the products’ status of development, type of device, type of dose, route of administration, usability, mechanism of action, mode of injection, maximum volume of the device and availability of connected mobile application. In addition, the chapter lists the large volume wearable injectors for delivery of insulin, highlighting the aforementioned parameters for each of them and information on provision of CGM \ BGM systems.

Chapter 5 presents a product competitiveness analysis of all large volume wearable injectors based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 provides detailed profiles of key large volume wearable injectors manufacturers. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments and a comprehensive future outlook.

Chapter 7 provides tabulated profiles of drug device combination products and each profile include drug specifications, mechanism of action, development history, current status of development, and dosage and sales information.

Chapter 8 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to wearable injectors for the delivery of drugs in large volumes. For this analysis, we looked at the patents that have been published by various players since 1984. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), patent publication year, patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging areas and the leading industry players. The chapter also includes a patent benchmarking analysis and patent valuation analysis.

Chapter 9 provides insights on the popularity of large volume wearable injectors on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the period between January 2013 and September 2018, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords / phrases and social media activity of the most popular players with the comparison of the tweets associated with their product. It also presents a bubble analysis of the most influential authors related to large volume wearable injectors on Twitter.

Chapter 10 presents a comprehensive clinical trial analysis of the complete and active studies being conducted to evaluate the combinations of drugs and large volume wearable injectors. For the purpose of this analysis, we looked at the clinical studies for these devices which started in 2010, and analyzed them on the basis of various parameters, such as trial start year, current trail status, current trial phase, study design, targeted therapeutic area, study focus and clinical outcomes.

Chapter 11 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of a wearable injector. It includes a short description of the manufacturing services provided by these organizations in the making of device components (primary containers), infusion sets, adhesives, closures and injection moldings. In addition, it presents a world map highlighting the location of the CMOs and their device manufacturing service portfolio.

Chapter 12 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via large volume wearable injectors in the future. It is worth highlighting that this list was compiled based on various parameters, such as route of administration, target therapeutic indication and the current dosage regimen of the aforementioned product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a large volume wearable injector in the future was estimated using the weighted average method.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of large volume wearable injectors, till the year 2030. We have segregated the opportunity on the basis of the therapeutic area, geographical distribution of the market (North America / Europe / Asia Pacific / RoW), type of device (patch pump / injector and infusion pump / injector) and usability (reusable / disposable). In addition, the chapter features an opportunity analysis of the of the large volume wearable injectors for delivery of insulin.

Chapter 14 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a comprehensive SWOT framework.

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Mark Banister (CEO, Medipacs), Pieter Muntendam (President and CEO, scPharmaceuticals), Mindy Katz (Director of Product, Sorrel Medical), Jesper Roested (CEO, Subcuject), Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains a list of companies and organizations mentioned in this report.

LIST OF COMPANIES

1 3M
2 Abbott
3 AbbVie
4 AbGenomics
5 Ablynx
6 Acceleron Pharma
7 Actavis Pharma
8 ADC Therapeutics
9 Adrenomed
10 Aduro BioTech
11 Advaxis
12 Aeglea BioTherapeutics
13 Affibody
14 Affimed
15 Agenus
16 AgonOx
17 Akesobio Australia
18 Alder BioPharmaceuticals
19 Alector
20 Alexion Pharmaceuticals
21 Alkahest
22 Alkermes
23 Allakos
24 Allergan
25 Allozyne
26 Alnylam Pharmaceuticals
27 AlphaCore Pharma
28 Altor BioScience
29 Ambrx
30 amcure
31 Amgen
32 Amicus Therapeutics
33 Amphivena Therapeutics
34 Amplyx Pharmaceuticals
35 Amylin Pharmaceuticals
36 Angiochem
37 Animas
38 Antares Pharma
39 Antaros Medical
40 Aprea Therapeutics
41 Aptevo Therapeutics
42 argenx
43 Argos Therapeutics
44 ArmaGen
45 ARMO BioSciences
46 Aronora
47 Asklepion Pharmaceuticals
48 Astellas Pharma
49 AstraZeneca
50 Atridia
51 AVEO Pharmaceuticals
52 Axon Neuroscience
53 Bang & Olufsen Medicom
54 Baril
55 Basilea Pharmaceutica
56 Battelle
57 Baxter International
58 Bayer
60 Bayhill Therapeutics
61 Becton Dickinson
62 BeiGene
63 Beijing Dongfang Biotech
64 Bespak
65 BioArctic
66 BIOCAD
67 bioCSL
68 Biogen
70 BioIntegrator
71 Bioject Medical Technologies
72 BioMarin Pharmaceutical
73 Bioniz Therapeutics
74 BioNTech
75 Bio-Path Holdings
76 Biotest Pharmaceuticals
77 Bio-Thera Solutions
78 Boehringer Ingelheim
79 Boston Pharmaceuticals
80 Bristol Myers Squibb
81 Calando Pharmaceuticals
82 Calibra Medical
83 CANbridge Life Sciences
84 Cancer Advances
85 Cara Therapeutics
86 Catalyst Biosciences
87 Celgene
88 Celldex Therapeutics
89 Cellnovo
90 CEL-SCI
91 CeQur
92 Chimerix
93 CHO Pharma
94 Chugai Pharmaceutical
95 Cidara Therapeutics
96 Cleveland BioLabs
97 Conjupro Biotherapeutics
98 ContraFect
99 Cour Pharmaceutical Development
100 CSL Behring
101 CSPC Pharmaceutical Group
102 CStone Pharmaceuticals
103 CureTech
104 CytoDyn
105 Daikyo Seiko
106 Datwyler
107 Debiotech
108 DEKA
109 Dekkun
110 Delta-Fly Pharma
111 Dendreon
112 Dexcom
113 DiaMedica Therapeutics
114 Diamyd Medical
115 E3D Elcam Drug Delivery Devices
116 EG-GILERO
117 Eisai
118 Eli Lilly
119 Elusys Therapeutics
120 EMD Serono
121 Emergent BioSolutions
122 Enable Injections
123 Endo Pharmaceuticals
124 Endocyte
125 EnGeneIC
126 EOFlow
127 EpicentRx
128 Eternity Healthcare
129 European Pharma Group
130 F2G
131 Fabrico
132 FibroGen
133 Finox Biotech
134 Five Prime Therapeutics
135 Flex International
136 Flowonix Medical
137 Galaxy Biotech
138 Galena Biopharma
139 Genentech
140 GENERON
141 GeneScience Pharmaceuticals
142 Genexine
143 Genzyme
144 Gerresheimer
145 Gilead Sciences
146 GlaxoSmithKline
147 Glenmark Pharmaceuticals
148 Gliknik
150 Guangzhou Cellprotek Pharmaceutical
151 HAL Allergy
152 Halozyme Therapeutics
153 Hanmi Pharmaceutical
154 Haselmeier
155 Helsinn Healthcare
156 Hemispherx Biopharm
157 Hoffmann-La Roche
158 Huabo Biopharm
159 ImClone Systems
160 Immatics Biotechnologies
161 Immune Response BioPharma
162 ImmuneMed
163 ImmunGene
164 Immunocore
165 ImmunoFrontier
166 ImmunoGen
167 Immunomedics
168 Immunotope
169 Immunovaccine
170 Implicit Bioscience
171 Incuron
172 Incyte
173 Injex Pharma
174 Innate Pharma
175 Innovent Biologics
176 Inovio Pharmaceuticals
177 Insulet
178 iNtRON Biotechnology
179 IO Biotech
180 Ionis Pharmaceuticals
182 Ipsen
183 ISU ABXIS
184 Janssen
186 Jerini
187 JHL Biotech
188 Jiangsu Hengrui Medicine
189 Jiangsu T-Mab Biopharma
190 Johnson & Johnson
191 Jounce Therapeutics
192 kaleo
193 KaloBios Pharmaceuticals
194 Kiniksa Pharmaceuticals
195 Kissei Pharmaceutical
196 Kura Oncology
197 Kyowa Hakko Kirin
198 Labrys Biologics
199 Leadiant Biosciences
200 LEO Pharma
201 Levicept
202 Life Science Pharmaceuticals
203 MabVax Therapeutics
204 MacroGenics
205 Medical International Technology
206 MedImmune
207 Medipacs
208 MedPro Safety Products
209 Medtronic
210 Medtrum Technologies
211 Menarini Group
212 Merck
213 Merck Sharp & Dohme
214 Mereo BioPharma
215 Meridian Medical Technologies
216 Merrimack Pharmaceuticals
217 Mersana Therapeutics
218 Merus
219 Merz Pharma
220 Millennium Pharmaceuticals
221 MiNA Therapeutics
222 miRagen Therapeutics
223 Mitsubishi Tanabe Pharma
224 Moderna Therapeutics
225 Molecular Partners
226 Molecular Templates
227 MolMed
228 MorphoSys
229 Morphotek
230 MTD Micro Molding
231 Mylan
232 NantBioScience
233 Naurex
234 Navidea Biopharmaceuticals
235 Neogenix Oncology
236 Neon Therapeutics
237 NeuroDerm
238 Nordic Bioscience
239 Northern Biologics
240 Novartis Pharmaceuticals
241 Novimmune
242 NOVO Engineering
243 Novo Nordisk
244 OBI Pharma
245 Octapharma
246 Omeros
247 Oncology Venture
248 OncoMed Pharmaceuticals
249 OncoPep
250 Oncopeptides
251 Oncternal Therapeutics
252 Oncurious
253 Opthea
254 Optimer Pharmaceuticals
255 OSE Immunotherapeutics
256 Otsuka Pharmaceutical
257 Paion UK
258 Pfizer
259 PharmaJet
260 PharmaMar
261 PharmaSens
262 PhaseBio Pharmaceuticals
263 Phillips-Medisize
264 Philogen
265 Phosplatin Therapeutics
266 Pierre Fabre
267 Pique Therapeutics
268 Polaris Group
269 Polyphor
270 Prescient Therapeutics
271 Prestige BioPharma
272 Promedior
273 Prometheus Laboratories
274 Protalix Biotherapeutics
275 Proven Process Medical Devices
276 Quest PharmaTech
277 Quintessence Biosciences
278 Ratio Drug Delivery
279 RAUMEDIC
280 Recro Pharma
281 Regeneron Pharmaceuticals
282 REMD Biotherapeutics
283 Resolve Therapeutics
284 rEVO Biologics
285 Rhythm Pharmaceuticals
286 Roche
287 Roehr pharmaceuticals
288 R-Pharm
289 Sagentia
290 Samsung Bioepis
291 Sandoz
292 Sanofi
294 Santarus
295 Savient Pharmaceuticals
296 scPharmaceuticals
297 Seattle Genetics
298 Selecta Biosciences
299 Selexys Pharmaceuticals
300 Sensile Medical
301 Serina Therapeutics
302 Shire
303 SMC Global
304 Smiths Medical
305 Sonceboz
306 SOOIL Development
307 SteadyMed Therapeutics
308 Stealth BioTherapeutics
309 Stemline Therapeutics
310 Stevanato Group
311 Subcuject
312 Sumitomo Dainippon Pharma
313 Sunovion Pharmaceuticals
314 SymBio Pharmaceuticals
315 Symphogen
316 Synectics
317 Synermore Biologics
318 Syntimmune
319 Syros Pharmaceuticals
320 TaiMed Biologics
321 Taiwan Liposome Company
322 Takeda Pharmaceutical
323 Tandem Diabetes Care
324 Tanvex BioPharma
325 Tarveda Therapeutics
326 Teva Pharmaceutical
327 TG Therapeutics
328 Tolero Pharmaceuticals
329 TRACON Pharmaceuticals
330 Translational Sciences
331 Turnstone Biologics
332 United BioPharma
333 Vaccinex
334 Vaccinogen
335 Valtronic
336 vasopharm BIOTECH
337 Verily Life Sciences
338 Vetter Pharma
339 ViCentra
340 Viela Bio
341 ViiV Healthcare
342 Visterra
343 Vitaeris
344 Vivozon
345 Weibel CDS
346 West Pharmaceutical Services
347 Wockhardt
348 Xbiotech
349 Xencor
350 XOMA
351 Ypsomed
352 Zafgen
353 Zollner